Clinical trials: Malignancy, Hematologic, open to volunteers
HIV, Hematologic Malignancies
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a…
- Trial name
- NCT05470491
- Testing
- RIC, GVHD prophylaxis, allo HCT
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Hematologic Malignancy
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Background: Many advances have been made in cancer treatments, but more research is needed. Comparing samples of cancerous tissue to samples of normal, noncancerous tissues may help find differences between them.
- Conditions
- Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer, Liver Cancer
- Trial name
- NCT05600933
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care…
- Conditions
- Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT05745285
- Testing
- LLS Program
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Miami
VEXAS, VEXAS Syndrome
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome.
- Trial name
- NCT06782373
- Testing
- Pacritinib
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Swedish Orphan Biovitrum
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
Hematologic Malignancies, Hematologic Neoplasms
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone.
- Trial name
- NCT07162038
- Testing
- mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies, Waldenstroms Macroglobulinaemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's…
- Conditions
- Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
- Trial name
- NCT04728893
- Testing
- Nemtabrutinib
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 490 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients…
- Conditions
- Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Trial name
- NCT07424833
- Testing
- APG-3288
- Where
- 6 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Ascentage Pharma Group Inc.
Transplant-Related Hematologic Malignancy
GM-CSF With Post-Transplant Cyclophosphamide
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the…
- Trial name
- NCT04237623
- Testing
- Sargramostim, Control Arm
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northside Hospital, Inc.
Hematologic Malignancy
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
- Trial name
- NCT05417971
- Testing
- Fludarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Kidney Failure Chronic, Stem Cell Transplant
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor…
- Conditions
- Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance
- Trial name
- NCT07358195
- Testing
- Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Secondary Immune Deficiency
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor…
- Trial name
- NCT07648264
- Testing
- IgPro20
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Hematologic Malignancies, Hematopoietic Stem Cell Transplantation
Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation
This study investigates whether a resistance training program can help patients recovering from hematopoietic stem cell transplantation (HSCT) for hematologic malignancies.
- Conditions
- Hematologic Malignancies, Hematopoietic Stem Cell Transplantation, Resistance Training, Neutropenia
- Trial name
- NCT07872813
- Testing
- 8-week Elastic Band Resistance Training Program
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
HLA/AAV Sensitization, Auto-immune Diseases
Real-world Clinical Effectiveness & Safety LV009, an in Vivo CAR-T for the Treatment of Hematologic Cancers, Auto-immune Diseases & HLA/ AAV Sensitization.
The study objective is to determine the real-world safety and effectiveness of LV009 therapy for 3 potential indications: (1) refractory or relapsed hematologic cancers (acute lymphoblastic Leukemia, B cell Lymphomas, multiple…
- Conditions
- HLA/AAV Sensitization, Auto-immune Diseases, Hematologic Cancers
- Trial name
- LV009 (NCT07873476)
- Testing
- LV009
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Healthy Malaysia Association
Hematological Malignancy
KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
- Trial name
- NCT07873827
- Testing
- MEN2312
- Volunteers
- 115 people
- Sponsor
- Stemline Therapeutics, Inc.
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death
- Trial name
- NCT05724121
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations.
- Trial name
- NCT07007312
- Testing
- Ziftomenib, Venetoclax, Azacitidine (AZA)
- Where
- 136 sites in United States, Australia and 15 more
- Volunteers
- 1,300 people
- Sponsor
- Kura Oncology, Inc.
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory